Mainz Biomed Valuation
| MYNZ Stock | USD 6.97 0.18 2.65% |
At this time, the firm appears to be overvalued. Mainz Biomed BV secures a last-minute Real Value of $4.51 per share. The latest price of the firm is $6.97. Our model forecasts the value of Mainz Biomed BV from analyzing the firm fundamentals such as Operating Margin of (18.83) %, return on equity of -43.34, and Shares Outstanding of 2 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Mainz Biomed's valuation include:
Price Book 1.715 | Enterprise Value 21.3 M | Enterprise Value Ebitda (2.84) | Price Sales 15.2191 | Enterprise Value Revenue 23.1696 |
Overvalued
Today
Please note that Mainz Biomed's price fluctuation is out of control at this time. Calculation of the real value of Mainz Biomed BV is based on 3 months time horizon. Increasing Mainz Biomed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Mainz Biomed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mainz Stock. However, Mainz Biomed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.97 | Real 4.51 | Target 9.67 | Hype 6.97 |
The intrinsic value of Mainz Biomed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mainz Biomed's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mainz Biomed BV helps investors to forecast how Mainz stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mainz Biomed more accurately as focusing exclusively on Mainz Biomed's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Mainz Biomed's intrinsic value based on its ongoing forecasts of Mainz Biomed's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Mainz Biomed's closest peers.
Mainz Biomed Cash |
|
Mainz Valuation Trend
Analysing the historical paterns of Mainz Biomed's enterprise value and its market capitalization is a good way to estimate and gauge the value of Mainz Biomed BV over time and is usually enough for investors to make rational market timing decisions.
Mainz Biomed Total Value Analysis
Mainz Biomed BV is now estimated to have valuation of 21.25 M with market capitalization of 13.96 M, debt of 7.42 M, and cash on hands of 26.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Mainz Biomed fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.25 M | 13.96 M | 7.42 M | 26.01 M |
Mainz Biomed Investor Information
The company has price-to-book ratio of 1.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mainz Biomed BV recorded a loss per share of 44.4. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 3rd of December 2024. Based on the measurements of operating efficiency obtained from Mainz Biomed's historical financial statements, Mainz Biomed BV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Mainz Biomed Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mainz Biomed has an asset utilization ratio of 5.81 percent. This suggests that the Company is making $0.0581 for each dollar of assets. An increasing asset utilization means that Mainz Biomed BV is more efficient with each dollar of assets it utilizes for everyday operations.Mainz Biomed Ownership Allocation
The market capitalization of Mainz Biomed BV is $13.96 Million. Mainz Biomed BV secures 5.79 % of its outstanding shares held by insiders and 0.25 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Mainz Biomed Profitability Analysis
The company reported the previous year's revenue of 895.48 K. Net Loss for the year was (26.3 M) with profit before overhead, payroll, taxes, and interest of 177.62 K.About Mainz Biomed Valuation
Our relative valuation model uses a comparative analysis of Mainz Biomed. We calculate exposure to Mainz Biomed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mainz Biomed's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 509.7 K | 535.1 K | |
| Pretax Profit Margin | (29.36) | (30.83) | |
| Operating Profit Margin | (29.75) | (31.24) | |
| Net Loss | (29.36) | (30.83) | |
| Gross Profit Margin | 0.57 | 0.60 |
Mainz Biomed Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.2 M |
Mainz Biomed Current Valuation Indicators
Valuation refers to the process of determining the present value of Mainz Biomed BV and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Mainz we look at many different elements of the entity such as Mainz's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Mainz Biomed, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Mainz Biomed's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Mainz Biomed's worth.Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.